Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-810 for Impulsive Aggression in Adolescents with ADHD
NCT03597503Phase 3Terminated
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jul 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of molindone in intermittent explosive disorder (IED), sponsored by Supernus Pharmaceuticals, Inc.. Started Jul 2018; status: terminated.
02
Drugs
molindone
03
Conditions
intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT03597503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03597503.